Abu Dhabi, March 7 -- A 44-day-old infant, diagnosed with the rare genetic disease Spinal Muscular Atrophy type 1 (SMA 1), has received the Zolgensma injection, a pioneering medicine used to combat this genetic disease. The successful administration of this groundbreaking gene therapy has been made possible due to early detection and swift collaboration between multiple stakeholders, including Burjeel Hospital, Abu Dhabi, and the authorities.
The journey of baby H. Al Ameri began when his vigilant mother noticed unusual signs shortly after his birth. Slow movement, a lack of crying, and a soft voice raised concerns that prompted the family to seek medical advice. A genetic test revealed the presence of spinal muscular atrophy type 1- an of...